Komori
PRISM BioLab (206A) · InitiativeAdvanced

Expanding PepMetics into established large markets, including kinases and membrane proteins

First written in 2026-05-18. 2 of 3 entries say "Advanced", first in 2026-06-15. Latest entry: 2026-08-14.

3entries
1years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst stated2026-05-18Advanced2026-06-15 – 2026-08-142026: 32026
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
Moved together

"Managing the Number of Programs at Each R&D Stage as a Progress Indicator" moved the same way as this thread, in the same document, in 2 of its 3 moves.

2★1
  1. ★This thread
  2. 1Managing the Number of Programs at Each R&D Stage as a Progress Indicator2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PRISM BioLab yet. It last moved in the Earnings of 2026-08-14: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expanding PepMetics into established large markets, including kinases and membrane proteins | PRISM BioLab Co.,LTD (206A) | Komori